Breast cancer

Accent Therapeutics Presents Data Supporting Two Lead Programs at AACR 2024 Annual Meeting

Retrieved on: 
Monday, April 8, 2024
BRCA, DNA repair, Mitosis, Apoptosis, Breast, PD, RME, Patient, DHX9, Neoplasm, Data, RNA, DNA, Cancer, Accent, Enzyme, AACR, Therapy, Breast cancer, BRCA2, Pharmaceutical industry

LEXINGTON, Mass., April 8, 2024 /PRNewswire/ -- Accent Therapeutics, a biopharmaceutical company pioneering a novel class of small molecule precision cancer therapeutics presents advances in cancer targeting, including data on DHX9 and KIF18A inhibitor activity in multiple tumor types, at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego, California.

Key Points: 
  • "Accent has expanded the potential of our two lead programs in preclinical investigations, and we are excited for the promise they hold for addressing cancers with high unmet clinical need," said Robert A. Copeland, Ph.D., President, Founder, and Chief Scientific Officer of Accent Therapeutics.
  • "Our results reveal that DHX9 and KIF18A inhibition are potent therapeutic strategies that stand to benefit large patient populations.
  • These findings validate our systematic approach to tapping the rich therapeutic potential of our target space."
  • These data are highlighted in a presentation entitled "DHX9 inhibition as a novel therapeutic for cancer with loss-of-function mutations in DNA damage repair genes BRCA1 and BRCA2."

Lunit's AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals

Retrieved on: 
Monday, April 8, 2024
Diagnosis, Istanbul University, Marmara University, Tekirdağ Namık Kemal University, Research, Mammography, Cancer, AI, Woman, MMG, Breast cancer, Workload, Therapy, ESR, Medical imaging

SEOUL, South Korea, April 8, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the publication of a new study, highlighting the effectiveness of Lunit INSIGHT MMG in significantly reducing radiologists' workload while enhancing cancer detection rates.

Key Points: 
  • This comprehensive study encompassed over 22,621 mammograms from 8,825 women over a decade.
  • Utilizing Lunit INSIGHT MMG, Lunit's AI-powered solution for breast cancer detection, the research aimed to assess its proficiency in early cancer detection within a breast cancer screening program.
  • This indicates a substantial step forward in improving the efficiency of breast cancer screening programs, potentially enabling broader screening coverage and reducing the burden on healthcare systems.
  • The study further revealed that the AI system identified 51.72% of interval cancers, and 50% of missed cancers.

i-Health, Inc. Urges U.S. Congressional Leaders to Prioritize the Funding of Natural & Non-Hormonal Solutions for Menopause in Women's Health Research

Retrieved on: 
Monday, April 8, 2024
Health, Attention, Congress, Government, Veteran, White, SVP, Executive order, Research, Menopause, History, Woman, Data collection, Hormone replacement therapy, Breast cancer, HRT, Hot, Amerifit Brands

i-Health, Inc. starts discussions with Congress to enhance research and funding for non-hormonal menopause options.

Key Points: 
  • i-Health, Inc. starts discussions with Congress to enhance research and funding for non-hormonal menopause options.
  • Research gaps are especially prevalent for health conditions associated with women's midlife and later years, including perimenopause and menopause."
  • The latest Executive Order from President Biden aims to close research gaps on women's health across their lifespans.
  • i-Health, Inc. the company behind Estroven®, the leading brand in natural, non-hormonal menopause relief‡, is committed to driving meaningful change for often overlooked health issues.

Sapience Therapeutics Presents Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Monday, April 8, 2024
Research, BCL9, MDSC, Survival, Patient, Wisdom, SVP, Neoplasm, The central science, Cancer, Macrophage, AP-1, IND, AACR, TAM, Phenotype, Therapy, Breast cancer, Poster, Cell, AP-1 transcription factor, TNBC, Metastasis, Vaccine

TARRYTOWN, N.Y., April 8, 2024 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today announced the presentation of new data on its clinical and pipeline programs during three poster presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024, in San Diego, CA.

Key Points: 
  • We look forward to ST316 and ST101 continuing to advance through clinical development and moving our AP-1 program into IND-enabling studies."
  • Sapience scientists will present non-clinical immune-oncology results from both of its clinical programs, ST316, a first-in-class antagonist of β-catenin, and ST101, a first-in-class antagonist of C/EBPβ.
  • In nonclinical studies, Sapience evaluated the ability of ST316 to enhance anti-tumor immune responses in combination with anti-PD-1 and anti-TIGIT therapies.
  • JunAP demonstrates potent anti-tumor activity in vivo in mouse triple negative breast cancer and melanoma tumor models.

USPS Honors Betty Ford

Retrieved on: 
Friday, April 5, 2024
Women's rights, Carnegie Hall, Equal Rights Amendment, Mastectomy, Newsroom, United, USPS, Republican Party, Disease, Betty Ford, Representative, Post, History, Female, Sale, Ford, Humour, Life, House, Collection, Betty Ford Center, Woman, Neck, News, Watergate scandal, Post office, White House Historical Association, Supreme court, Louisiana House of Representatives, The Postal Service, Breast cancer, Family, Hazelden Betty Ford Foundation, McReynolds, Divorce, Mail

RANCHO MIRAGE, Calif., April 5, 2024 /PRNewswire/ -- Today, the Postal Service issued a commemorative stamp celebrating the life of former First Lady Betty Ford on the campus of Eisenhower Health, adjacent to the Betty Ford Center in Rancho Mirage, CA. She was the wife of Gerald R. Ford, the 38th president, and widely admired for her support of women's rights and her candor about the serious health challenges she faced.

Key Points: 
  • RANCHO MIRAGE, Calif., April 5, 2024 /PRNewswire/ -- Today, the Postal Service issued a commemorative stamp celebrating the life of former First Lady Betty Ford on the campus of Eisenhower Health, adjacent to the Betty Ford Center in Rancho Mirage, CA.
  • Also attending were Susan Ford Bales, Betty Ford's daughter; Marty Massiello, CEO of Eisenhower Health; Dr. Joseph Lee, president and CEO of the Hazelden Betty Ford Foundation; and Tessa Voss, also of the foundation.
  • Betty Ford did that for both breast cancer and addiction — replacing shame and isolation with dignity, community and equitable care," Lee said.
  • In 1982, Ford and Leonard Firestone, a former ambassador and family friend, established the Betty Ford Center substance use disorder treatment center, which is now part of the nonprofit Hazelden Betty Ford Foundation.

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, March 25, 2024
Rated R, Fulvestrant, KICKSTART, Patient, Sale, G&A, Investment, Therapy, Anemia, Vomiting, Artificial intelligence, Effector, Research, Science, AML, Expense, Pembrolizumab, Breast cancer, Safety, Fatigue, PD-L1, Database, NSCLC, Associate, Cancer, University, PFS, Hematology, FDA, OS, Azacitidine, ZF, Administration, Assistant, MNK, Progression-free survival, COVID-19, Fast Track, Messenger, Cell, Nausea, Research and development, DARPA, Interval (mathematics), Pharmaceutical industry

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • The primary analysis will reflect 37 PFS events, which provides approximately 80% power to detect a PFS hazard ratio of 0.65 at a p≤0.2.
  • Revenue: Revenue was zero for the quarter ended December 31, 2023, compared to approximately $0.7 million for the same quarter of 2022.
  • Research and Development (R&D) Expenses: R&D expenses were $6.1 million for the quarter ended December 31, 2023, compared to $6.6 million for the same quarter of 2022.
  • The earn-out period expired in August 2023 resulting in a reduction of the corresponding earn-out liability to zero as of December 31, 2023.

GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare

Retrieved on: 
Monday, March 25, 2024
Ovarian cancer, Health, Comprehensive, Cardiovascular disease, Gene, Genetic testing, DSM-IV codes, Risk, Patient, HBOC, Breast, Risk assessment, Publication, Cancer, Breast cancer, Physician, Vaccine

Oncology, Cardiovascular, and Metabolic Disease Coverage: GeneType's Comprehensive Risk Assessment Test covers a diverse range of diseases, providing physicians and patients with a complete understanding of an individual's risk profile.

Key Points: 
  • Oncology, Cardiovascular, and Metabolic Disease Coverage: GeneType's Comprehensive Risk Assessment Test covers a diverse range of diseases, providing physicians and patients with a complete understanding of an individual's risk profile.
  • With an increasing emphasis on personalized medicine and preventative healthcare, the demand for comprehensive genetic risk assessments is expected to grow significantly.
  • GENE’s CEO Simon Morriss, commented “As pioneers in risk assessment testing, we are thrilled to introduce our latest GeneType Comprehensive Risk Assessment Test.
  • The Comprehensive Risk Assessment Test marks a significant step towards realizing this vision, offering a transformative tool for healthcare providers and their patients.

Prevent Cancer Foundation to visit Comadre a Comadre in Albuquerque

Retrieved on: 
Friday, March 22, 2024
Health, Education, Cervical cancer, Patient, Lung, NCI-designated Cancer Center, UNM, University, Breast, Cancer, Doctor of Philosophy, Compadre, Woman, HPV, Survivor, Yoli, Breast cancer, Vaccination, Liver, Skin, Birth control

Alexandria, Va., March 22, 2024 (GLOBE NEWSWIRE) -- On March 25, representatives of the Prevent Cancer Foundation® and its Congressional Families® Program will visit Comadre a Comadre, recipient of a $25,000 grant providing breast cancer education and navigation to Hispanic/Latina women across New Mexico.

Key Points: 
  • Alexandria, Va., March 22, 2024 (GLOBE NEWSWIRE) -- On March 25, representatives of the Prevent Cancer Foundation® and its Congressional Families® Program will visit Comadre a Comadre, recipient of a $25,000 grant providing breast cancer education and navigation to Hispanic/Latina women across New Mexico.
  • Lisa McGovern, Executive Director of the Congressional Families Program, and Erica Childs-Warner, Managing Director, Research, Education and Outreach, will represent the Prevent Cancer Foundation, joined by Rep. Teresa Leger Fernández (NM-03).
  • They deserve and have earned this national recognition and $25,000 grant from the Prevent Cancer Foundation to continue providing essential services for Latinas in New Mexico.
  • The Prevent Cancer Foundation is proud to support Comadre a Comadre in their work to reach this community and improve access to lifesaving screenings.

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights

Retrieved on: 
Thursday, March 21, 2024
Administration, Head, TIL, Colorectal cancer, Immunotherapy, HNSCC, Takeda Oncology, Selection, Patient, G&A, Melanoma, TILS, Investment, CRC, Breast cancer, SITC, Research and development, Research institute, Turnstone, Uveal melanoma

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights.

Key Points: 
  • “2023 marked a transformative year for Turnstone Biologics in which we transitioned into a publicly traded company and continued to advance our pipeline through clinical development.
  • Recently, Turnstone expanded their trials to evaluate additional solid tumor types in addition to the existing indications of breast cancer and uveal melanoma.
  • Preclinical Data Presentations at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting Support Ongoing Clinical and Preclinical Efforts.
  • Cash, Cash Equivalents and Short-Term Investments: As of December 31, 2023, cash, cash equivalents and short-term investments were $94.8 million.

Bionano Announces Publication of a Breast Cancer Study Showing that the Number of SVs Detected with OGM May Be Related to Prognosis, Tumor Progression and Chemotherapy Resistance

Retrieved on: 
Tuesday, March 19, 2024
Ovarian cancer, DNA repair, Breast, SAN, Neoplasm, DNA, HBOC, Doctor of Philosophy, Medicine, Genomics, Chromothripsis, SVS, Breast cancer, HRD, BRCA2, OGM, BRCA1, Drug resistance, Medical imaging

HBOC syndrome is estimated to cause 5-10% of all breast cancers and is commonly characterized by harmful germline mutations in the BRCA1 or BRCA2 genes.

Key Points: 
  • HBOC syndrome is estimated to cause 5-10% of all breast cancers and is commonly characterized by harmful germline mutations in the BRCA1 or BRCA2 genes.
  • The study authors selected OGM for this analysis due to its ability to detect multiple classes of SVs with genome-wide coverage, high resolution and accuracy.
  • Eight novel gene fusions were identified by OGM, including three that had not previously been detected by other methods of analysis.
  • “We are pleased to see the publication of this study, which highlights OGM as a promising tool for detecting novel variants in HBOC-related breast cancer that have oncogenic potential.